Terms: = Liver cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
300 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and treatment Implications.
Li J; Zhang L; Ge T; Liu J; Wang C; Yu Q
Drug Des Devel Ther; 2024; 18():829-843. PubMed ID: 38524877
[TBL] [Abstract] [Full Text] [Related]
3. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract] [Full Text] [Related]
4. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Kato T; Mizuno R; Miyake H
Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663
[TBL] [Abstract] [Full Text] [Related]
5. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
6. Anti-hepatocellular carcinoma activity of Sorbaria sorbifolia by regulating vegfr and c-Met/apoptotic pathway.
Xu ZH; Dang Y; Dong Y; Dong CY; Liu Y; Chen X; Yao Z; Shi JP
J Ethnopharmacol; 2024 Apr; 324():117758. PubMed ID: 38246481
[TBL] [Abstract] [Full Text] [Related]
7. Anti-cancer activity and cellular uptake of 7,3',4'- and 7,8,4'-trihydroxyisoflavone in HepG2 cells under hypoxic conditions.
Tzeng WS; Teng WL; Huang PH; Yen FL; Shiue YL
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2288806. PubMed ID: 38153119
[TBL] [Abstract] [Full Text] [Related]
8. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
10. Camrelizumab (a PD-1 inhibitor) plus apatinib (an vegfr-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic liver cancer stage C (TRIPLET): a phase II study.
Zhang TQ; Geng ZJ; Zuo MX; Li JB; Huang JH; Huang ZL; Wu PH; Gu YK
Signal Transduct Target Ther; 2023 Oct; 8(1):413. PubMed ID: 37884523
[TBL] [Abstract] [Full Text] [Related]
11. pH-Responsive and Actively Targeted Metal-Organic Framework Structures for Multimodal Antitumor Therapy and Inhibition of Tumor Invasion and Metastasis.
Jia W; Jin B; Xu W; Liu S; Mao X; Peng H; Zhang Y
ACS Appl Mater Interfaces; 2023 Nov; 15(43):50069-50082. PubMed ID: 37871135
[TBL] [Abstract] [Full Text] [Related]
12. Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.
Zhang L; Xu J; Zhou S; Yao F; Zhang R; You W; Dai J; Yu K; Zhang Y; Baheti T; Pu L; Xu J; Qian X; Zhang C; Xia Y; Dai X; Li Q; Wang X
J Hepatol; 2024 Jan; 80(1):82-98. PubMed ID: 37838036
[TBL] [Abstract] [Full Text] [Related]
13. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
[TBL] [Abstract] [Full Text] [Related]
14. In vivo self-assembly and delivery of vegfr2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.
Yu L; Fan G; Wang Q; Zhu Y; Zhu H; Chang J; Wang Z; Zhan S; Hua X; She D; Huang J; Wang Y; Zhao J; Zhang CY; Chen X; Zhou G
Cell Death Dis; 2023 Sep; 14(9):626. PubMed ID: 37739958
[TBL] [Abstract] [Full Text] [Related]
15. [Apatinib Suppressed Macrophage-Mediated Malignant Behavior of Hepatocellular Carcinoma Cells via Modulation of vegfr2/STAT3/PD-L1 Signaling].
Yin T; Fu CB; Wu DD; Nie L; Chen H; Wang Y
Mol Biol (Mosk); 2023; 57(4):706-708. PubMed ID: 37528791
[TBL] [Abstract] [Full Text] [Related]
16. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S; Chan SL; Gu S; Bai Y; Ren Z; Lin X; Chen Z; Jia W; Jin Y; Guo Y; Hu X; Meng Z; Liang J; Cheng Y; Xiong J; Ren H; Yang F; Li W; Chen Y; Zeng Y; Sultanbaev A; Pazgan-Simon M; Pisetska M; Melisi D; Ponomarenko D; Osypchuk Y; Sinielnikov I; Yang TS; Liang X; Chen C; Wang L; Cheng AL; Kaseb A; Vogel A;
Lancet; 2023 Sep; 402(10408):1133-1146. PubMed ID: 37499670
[TBL] [Abstract] [Full Text] [Related]
17. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.
Xu S; Dong K; Gao R; Yang Y; Zhou Y; Luo C; Chen W; Liu SM
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12249-12263. PubMed ID: 37434092
[TBL] [Abstract] [Full Text] [Related]
18. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
19. The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms.
Jiang H; Liao J; Wang L; Jin C; Mo J; Xiang S
Front Immunol; 2023; 14():1163967. PubMed ID: 37325670
[TBL] [Abstract] [Full Text] [Related]
20. Supramolecular Polymer-Nanomedicine Hydrogel Loaded with Tumor Associated Macrophage-Reprogramming polyTLR7/8a Nanoregulator for Enhanced Anti-Angiogenesis Therapy of Orthotopic Hepatocellular Carcinoma.
Liu X; Huangfu Y; Wang J; Kong P; Tian W; Liu P; Fang C; Li S; Nie Y; Feng Z; Huang P; Shi S; Zhang C; Dong A; Wang W
Adv Sci (Weinh); 2023 Aug; 10(22):e2300637. PubMed ID: 37229748
[TBL] [Abstract] [Full Text] [Related]
[Next]
